- Home
- UAMY vs LPCN Comparison
UAMY vs LPCN Comparison
Compare UAMY & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- LPCN
- Stock Information
- Founded
- UAMY 1968
- LPCN 1997
- Country
- UAMY United States
- LPCN United States
- Employees
- UAMY N/A
- LPCN N/A
- Industry
- UAMY Metal Fabrications
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- LPCN Health Care
- Exchange
- UAMY Nasdaq
- LPCN Nasdaq
- Market Cap
- UAMY 251.9M
- LPCN 16.1M
- IPO Year
- UAMY N/A
- LPCN N/A
- Fundamental
- Price
- UAMY $2.22
- LPCN $3.25
- Analyst Decision
- UAMY Strong Buy
- LPCN Strong Buy
- Analyst Count
- UAMY 4
- LPCN 2
- Target Price
- UAMY $3.38
- LPCN $9.00
- AVG Volume (30 Days)
- UAMY 5.3M
- LPCN 61.6K
- Earning Date
- UAMY 08-08-2025
- LPCN 08-07-2025
- Dividend Yield
- UAMY N/A
- LPCN N/A
- EPS Growth
- UAMY N/A
- LPCN N/A
- EPS
- UAMY N/A
- LPCN N/A
- Revenue
- UAMY $18,865,900.00
- LPCN $3,674,834.00
- Revenue This Year
- UAMY $270.45
- LPCN N/A
- Revenue Next Year
- UAMY $104.06
- LPCN N/A
- P/E Ratio
- UAMY N/A
- LPCN N/A
- Revenue Growth
- UAMY 97.46
- LPCN N/A
- 52 Week Low
- UAMY $0.27
- LPCN $2.68
- 52 Week High
- UAMY $3.86
- LPCN $8.23
- Technical
- Relative Strength Index (RSI)
- UAMY 36.94
- LPCN 44.63
- Support Level
- UAMY $2.71
- LPCN $3.10
- Resistance Level
- UAMY $2.71
- LPCN $3.23
- Average True Range (ATR)
- UAMY 0.24
- LPCN 0.16
- MACD
- UAMY -0.08
- LPCN -0.00
- Stochastic Oscillator
- UAMY 17.67
- LPCN 19.76
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.